Dyadic International Inc. (DYAI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dyadic International, Inc. on January 28, 2020, covering events occurring between January 24, 2020, and January 27, 2020. The Company is a biotechnology firm incorporated in Delaware with its principal executive offices in Jupiter, Florida.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a Current Report regarding specific events and does not contain financial statements or performance metrics.
Material Changes
No material financial changes or operational updates were reported in this filing. The document serves solely to disclose media appearances by the Company's leadership.
Management Commentary and Events
- FOX Business Interview: On January 27, 2020, President and CEO Mark Emalfarb was interviewed on "The Claman Countdown" by Liz Claman.
- WPBF 25 News Interview: On January 24, 2020, Mr. Emalfarb was interviewed by WPBF 25 News. During this appearance, he urged U.S. pharmaceutical manufacturers to increase vaccine production in response to the spreading coronavirus.
- Exhibits: Press releases dated January 27, 2020 (Exhibit 99.1) and January 28, 2020 (Exhibit 99.2) are attached to this filing.
Key Facts for Investor Verification
- Verify the content of the CEO's statements regarding vaccine production capacity and the coronavirus situation via the provided links in the filing.
- Confirm that no financial data or material contracts were disclosed in this specific 8-K filing.
- Review the attached press releases (Exhibits 99.1 and 99.2) for additional context on the Company's strategic positioning during the early stages of the pandemic.